Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure: Maverick microglia

    Effectorless efficacy Targets & Mechanisms Maverick microglia Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AC Immune S.A. have shown that using standard mAbs to treat CNS diseases may …

    Published on 7/28/2016
  • Table: BioCentury Product Profile

    Effectorless efficacy Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product An anti-tau mAb incapable of binding microglia Concept Reduce tau pathology without …

    Published on 7/28/2016
  • Effectorless efficacy

    How Genentech is making mAbs safer for CNS diseases

    By designing therapeutic mAbs to fly under the radar of brain microglial cells, Genentech is making the modality safer for treating CNS diseases without sacrificing efficacy.

    Published on 7/28/2016
  • Figure: Crossing paths

    Making sense of sensors Targets & Mechanisms Crossing paths Since TLR9 was first identified as an innate immune receptor that detects microbial DNA and helps initiate a response to infection two decades ago, new …

    Published on 7/28/2016
  • Figure: Some like it hot

    Making sense of sensors Targets & Mechanisms Some like it hot Activation of nucleic acid sensors such as TLR9 can make so-called "cold" immunosuppressed tumors into "hot" ones that become infiltrated with antitumor…

    Published on 7/28/2016
  • Making sense of sensors

    Targeting nucleic acid sensors makes sense for cancer

    While TLRs have put nucleic acid sensors on the map, newer class members STING and RIG-I are raising interest as alternatives in immuno-oncology.

    Published on 7/28/2016
  • Figure: Triggering AD

    AChE revisited Targets & Mechanisms Triggering AD Neuro-Bio Ltd. has identified a peptide derived from AChE that is overexpressed in the brain centers that degenerate first in Alzheimer's disease (AD), and has …

    Published on 6/30/2016
  • Table: BioCentury Product Profile

    AChE revisited Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that inhibits binding of an AChE-derived peptide to CHRNA7 Concept Prevent …

    Published on 6/30/2016
  • AChE revisited

    Why Neuro-Bio thinks it's time to revisit the role of AChE in AD

    With a new take on an old target, Neuro-Bio believes a developmental form of AChE holds the key to slowing neurodegeneration in Alzheimer's disease.

    Published on 6/30/2016
  • Hide and seek

    A two-part strategy for chasing dormant breast cancer cells out of hiding

    A two-part mechanism discovered at Duke explains how breast cancer cells enter and hide in bone marrow, and suggests GlycoMimetics' next clinical compound could be used to flush them out.

    Published on 6/23/2016
  • Figure: Bad to the bone

    Hide and seek Targets & Mechanisms Bad to the bone A Duke University team has shown how breast cancer cells that have left the primary tumor invade the bone marrow to create dormant micrometastases capable of …

    Published on 6/23/2016
  • Table: BioCentury Product Profile

    Hide and seek Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product GMI-1359, a dual inhibitor of E selectin and CXCR4 Concept Drive dormant micrometastases out of…

    Published on 6/23/2016
  • Vedanta's horizons

    How microbiome company Vedanta is expanding its microbiome platform

    With a $50 million series B round and new technology, Vedanta is expanding its microbiome platform to turn up or down inflammation to fit the indication.

    Published on 6/16/2016
  • Figure: Axis of diabetes

    The Finnish connection Targets & Mechanisms Axis of diabetes An international research group has found that differences between the standards of living in Russia, Estonia and Finland are linked to differences in …

    Published on 6/16/2016
  • Figure: Battle of the bugs

    The Finnish connection Targets & Mechanisms Battle of the bugs In a study in Cell, an international consortium of researchers showed that susceptibility to Type I diabetes was affected by regional differences in …

    Published on 6/16/2016
  • The Finnish connection

    The microbiome link between Finnish children and Type I diabetes

    By comparing microbiomes of Finnish, Russian and Estonian infants, an international consortium has found a molecular link between Type I diabetes and Bacteroides bacteria.

    Published on 6/16/2016
  • Table: BioCentury Product Profile

    Vedanta's horizons Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Mixture of 20 Clostridium, Bifidobacterium, Ruminococcus and Bacteroides bacterial species …

    Published on 6/16/2016
  • Dissociating ketamine

    An NMDA receptor-independent ketamine metabolite might bypass the drug's side effects

    The discovery of a ketamine metabolite that alleviates depression without causing psychedelic effects could upend a major hypothesis about the drug's action.

    Published on 5/26/2016
  • Figure: Converting ketamine

    Dissociating ketamine Targets & Mechanisms Converting ketamine Collaborators at NIH and the University of Maryland used the structures of the (R) and (S) enantiomers of ketamine and its hydroxynorketamine (HNK) …

    Published on 5/26/2016
  • Figure: Ketamine mimics

    Dissociating ketamine Targets & Mechanisms Ketamine mimics The anesthetic ketamine is an NMDA receptor antagonist known to have antidepressant activity, but it also causes severe psychedelic side effects. In a …

    Published on 5/26/2016
  • Table: BioCentury Product Profile

    Dissociating ketamine Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product (2R,6R)-hydroxynorketamine Concept A ketamine metabolite that recapitulates the drug's …

    Published on 5/26/2016
  • Figure: NET inflammation in flu

    Another shot at the flu Targets & Mechanisms NET inflammation in flu A new study in Science from Yale University researchers suggests inhibiting caspase-1 and other caspases could help prevent the excessive …

    Published on 5/12/2016
  • Table: Biocentury Product Profile

    Another shot at the flu Targets & Mechanisms Biocentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Inhibitors of caspase-1, caspase-4 and caspase-5 Concept Blocking caspase-induced …

    Published on 5/12/2016
  • Another shot at the flu

    Targeting caspases may prevent flu-associated death in the elderly

    Human ex vivo studies and genetic analysis of a mouse model of flu in older humans have identified three caspases as new targets for treating flu in the elderly.

    Published on 5/12/2016
  • Figure: Taking down SAMMSON

    Better call Delilah Targets & Mechanisms Taking down SAMMSON In a study published in Nature, researchers from Catholic University Leuven, Flanders Institute for Biotechnology (VIB) and Ghent University showed the …

    Published on 5/5/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993